Quest Diagnostics (DGX), a key player in the bio-tech market, has seen a great deal of activity recently. The company increased its dividend to $0.80, released positive fourth quarter and full-year 2024 financial results, and raised its 2025 guidance. Following the announcement of these promising results, multiple large transactions took place including purchases by Bank of New York Mellon Corp and SVB Wealth LLC. To further push their growth plans into execution, Quest Diagnostics also announced acquisitions from Fresenius Medical Care and LifeLabs to broaden its laboratory services. They are also pacing toward advancing their technology in their labs with the acquisition of Select PathAI Diagnostics' Lab Assets, introducing AI and digital pathology for speeding up cancer diagnosis. Furthermore, they managed to reach the Fortune's World's Most Admired Companies List for the 11th consecutive year and continued to bolster its leadership team with key appointments. Looking at all these activities, Quest Diagnostics demonstrates value and potential for growth in its industry.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 01 Mar 2025 11:35:16 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -1
